Novan, Inc. (NOVN)

Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This

Novartis AG (SWX:NOVN) submitted a written non-binding indication of interest to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $200 million on April 4, 2025. Novartis AG (SWX:NOVN) entered into an agreement and plan of merger to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $540 million on April 29, 2025. Novartis submitted a written non-binding indication of interest to acquire the Company for $3.00 per share in cash and a CVR of $1.50 per share. Under the terms of the merger agreement, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of the consideration represents a premium of 274 percent to Regulus' 60-day volume-weighted average stock price and 108 percent to Regulus' closing price on April 29, 2025. In addition, Regulus shareholders will receive a contingent value right (CVR) providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate, farabursen. Total consideration including the CVR, if the milestone is achieved, would be approximately $1.7 billion. Upon the successful completion of the tender offer, a subsidiary of Novartis will be merged with and into Regulus and any remaining shares of common stock of Regulus will be cancelled and converted into the right to receive the same merger consideration (including the contingent value right) per share payable in the tender offer. Following completion of the tender offer, Novartis plans to merge the acquiring subsidiary with Regulus, making Regulus an indirect, wholly-owned subsidiary of Novartis. Until closing, Novartis and Regulus will continue to operate as separate and independent companies. The termination fee of $27.293938 million is payable by Regulus and $41.990674 million is payable by Novartis. The closing of the tender offer will be subject to certain conditions, including the tender of shares representing at least a majority of the total number of Regulus' outstanding shares, HSR act and other customary closing conditions and regulatory clearance. The transaction has been unanimously approved by the Boards of Directors of both companies. As of April 29, 2025, Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transactions contemplated by the Agreement and Plan of Merger. As on May 27, 2025, Novartis has commenced a tender offer to acquire all of the outstanding shares of common stock,The Offer will expire at one minute past 11:59 p.m., New York City time, on June 24, 2025, unless the Offer is otherwise extended or earlier terminated. As of June 24, 2025, 56,374,397 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74.49% of the issued and outstanding Shares immediately prior to the Expiration Time. The parties expect the transaction to close on June 25, 2025, promptly following the acceptance of all Shares validly tendered and not validly withdrawn pursuant to the Offer. Bradley Wolff, Francois Maisonrouge, Bobby Bal, Robert Fields of Evercore is serving as exclusive financial advisor and fairness opinion provider, and Charles Ruck, Daniel Rees, Betty Pang, Chad Jennings, Michelle L.C. Carpenter, Andrea Ramezan-Jackson, Heather Deixler, Steven Chinowsky, Robert Yeh, Paul Rosen, Nathan Seltzer and Joshua Holian of Latham & Watkins LLP is serving as legal counsel to Regulus. Innisfree M&A Incorporated acted as information agent and Computershare Trust Company, National Association acted as transfer agent to Novartis. Novartis AG (SWX:NOVN)completed the acquisition of Regulus Therapeutics Inc. (NasdaqCM:RGLS) on June 25, 2025.

– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan's assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing –

Novan, Inc. (NASDAQ:NOVN ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President & Chief Executive Officer John Donofrio - Executive Vice President & Chief Operating Officer John Gay - Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Jeff Jones - Oppenheimer Jonathan Aschoff - Roth Capital Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello and welcome to the Novan Inc. Quarterly Update Conference Call and Webcast.

DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Presentation with live webcast today, March 14th at 10:40 AM ET Presentation with live webcast today, March 14th at 10:40 AM ET

Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET

SAN DIEGO--( BUSINESS WIRE )--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (molluscum). Assuming the filing is accepted by the FDA and given a typical 12-month review process, Novan anticipates a potential first quarter 2024 approval.

Novan, Inc. (NASDAQ:NOVN ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President, and Chief Executive Officer John Gay - Chief Financial Officer John Donofrio - Chief Operating Officer and President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets John Vandermosten - Zacks Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

Novan, Inc. (NASDAQ:NOVN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Paula Stafford - President, CEO & Chairwoman John Gay - CFO & Corporate Secretary John Donofrio - EVP, COO & President, EPI Health Conference Call Participants Jeff Jones - Oppenheimer Brian Dolliver - Brookline Capital Markets Jonathan Aschoff - ROTH Capital Partners Oren Livnat - H.C. Wainwright & Co. John Vandermosten - Zacks Small-Cap Research Jennifer Kim - Cantor Fitzgerald & Co. Operator Hello, and welcome to the Novan, Inc. Quarterly Update Conference Call and Webcast.

DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday, August 11th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum –

Novan, Inc. (NASDAQ:NOVN ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Paula Brown Stafford - Chairman, President and Chief Executive Officer John Donofrio - Chief Operating Officer, Novan and President, EPI Health John Gay - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Fitzgerald Kemp Dolliver - Brookline Capital John Vandermosten - Zacks Jonathan Aschoff - Roth Capital Partners Operator Hello and welcome to the Novan, Incorporated Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May 16th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.

Novan, Inc. (NOVN) CEO Paula Brown Stafford on Q4 2021 Results - Earnings Call Transcript